206989-61-9

Usage

Uses

Used in Pharmaceutical Research:
4-ACETYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is used as a research chemical for the development of novel pharmaceuticals. Its unique structure and properties make it a promising candidate for the synthesis of new drugs and the study of various biological activities.
Used in Chemical Synthesis:
In the chemical industry, 4-ACETYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is used as a key intermediate in the synthesis of various organic compounds. Its versatile structure allows for further functionalization and modification, leading to the creation of a wide range of chemical products.
Used in Analytical Chemistry:
4-ACETYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is employed as a reference compound in analytical chemistry. Its distinct properties make it useful for the calibration of analytical instruments and the development of new analytical methods.
Used in Material Science:
In the field of material science, 4-ACETYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is used as a component in the development of new materials with specific properties. Its unique molecular structure can contribute to the creation of materials with enhanced performance characteristics.
Overall, 4-ACETYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is a versatile compound with a wide range of applications across various industries, including pharmaceutical research, chemical synthesis, analytical chemistry, and material science. Its unique properties and potential for further development make it an essential tool in the ongoing pursuit of scientific knowledge and technological advancements.

InChI:InChI=1/C12H21NO3/c1-9(14)10-5-7-13(8-6-10)11(15)16-12(2,3)4/h10H,5-8H2,1-4H3

Upstream product

• 917-64-6 methyl magnesium iodide 
• 91419-52-2 1-tert-butoxycarbonyl-4-cyanopiperidine 
• 75-16-1 methylmagnesium bromide 
• 139290-70-3 tert-butyl 4-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate 
• 39546-32-2 4-carboxamidopiperidine 
• 676-58-4 methylmagnesium chloride 
• 782493-40-7 tert-butyl 4-[(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidene)(hydroxy)methyl]piperidine-1-carboxylate 
• 479630-08-5 4-(2-ethoxycarbonylacetyl)piperidine-1-carboxylic acid tert-butyl ester 
• 498-94-2 isonipecotic acid 
• 137076-22-3 tert butyl 4-formylpiperidine-1-carboxylate 
• 287192-97-6 4-ethynyl-piperidine-1-carboxylic acid tert-butyl ester 
• 203664-61-3 4-(2,2-dibromo-vinyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 142851-03-4 1-tert-butyl 4-ethyl piperidine-1,4-dicarboxylate 
• 124443-68-1 1-tert-Butyl 4-methyl piperidine-1,4-dicarboxylate 

Downstream Products

• 301219-11-4 1-(1-(tert-Butoxycarbonyl)piperidin-4-yl)-4-phenyl-butane-1,3-dione 
• 479630-02-9 4-(2-methoxycarbonylacetyl)piperidine-1-carboxylic acid tert-butyl ester 
• 767321-32-4 4-[3-(2,3-dichloro-phenyl)-3-oxo-propionyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 550377-06-5 4-(5-oxo-4,5-dihydro-1H-pyrazol-3-yl)piperidine-1-carboxylic acid tert-butyl ester 
• 550377-00-9 4-[5-(2,3-dichlorophenyl)-1-methyl-1H-pyrazol-3-yl]piperidine-1-carboxylic acid tert-butyl ester 
• 716371-44-7 4-[5-(2,3-dichlorophenyl)-2-methyl-2H-pyrazol-3-yl]piperidine-1-carboxylic acid tert-butyl ester 
• 766545-84-0 4-[1-tert-butoxycarbonyl-5-(2,3-dichloro-phenyl)-1H-pyrazol-3-yl]-piperidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Meso-piperidine calix[4]pyrrole: Synthesis, structure and ion binding studies

We report the synthesis, structure and preliminary solution phase ion binding properties of the calix[4]pyrrole 3a-c. Calix[4]pyrrole 3a and 3b, the first to be prepared via one-pot reaction, were obtained by reacting the ketone 7 with pyrrole in the presence of an acid catalyst. On the basis of 1H NMR spectroscopic analyses and the titrations of UV spectrophotometry, it was concluded that compound 3a possesses significantly enhanced selectivity for fluoride anion in chloroform, and formes 1:1 (ligand: anion) complexes with fluoride and chloride anions.

Gold N-Heterocyclic Carbene Catalysts for the Hydrofluorination of Alkynes Using Hydrofluoric Acid: Reaction Scope, Mechanistic Studies and the Tracking of Elusive Intermediates

An efficient and chemoselective methodology deploying gold-N-heterocyclic carbene (NHC) complexes as catalysts in the hydrofluorination of terminal alkynes using aqueous HF has been developed. Mechanistic studies shed light on an in situ generated catalyst, formed by the reaction of Br?nsted basic gold pre-catalysts with HF in water, which exhibits the highest reactivity and chemoselectivity. The catalytic system has a wide alkyl substituted-substrate scope, and stoichiometric as well as catalytic reactions with tailor-designed gold pre-catalysts enable the identification of various gold species involved along the catalytic cycle. Computational studies aid in understanding the chemoselectivity observed through examination of key mechanistic steps for phosphine- and NHC-coordinated gold species bearing the triflate counterion and the elusive key complex bearing a bifluoride counterion.

TRPML MODULATORS

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

ATF6 MODULATORS AND USES THEREOF

Compounds (1-2) as modulators of Activating Transcription Factor 6 (ATF6) are provided. The compounds may find use as therapeutic agents for the treatment of diseases or disorders mediated by ATF6 and may find particular use in the treatment of viral infections, neurodegenerative diseases, vascular diseases, or cancer. (Formula (1-2))

TREATMENT OF INDOLENT OR AGGRESSIVE B-CELL LYMPHOMAS USING A COMBINATION COMPRISING BTK INHIBITORS

Disclosed herein is a method for the prevention, delay of progression or treatment of indolent or aggressive B-cell lymphomas in an individual in need thereof, comprising administering a Btk inhibitor (in particularly (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo-[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof) in combination with an anti-PD-1 antibody. The potent and selective BTK inhibitor in combination with the anti-PD-1 antibody have a manageable toxicity profile in patients with indolent and aggressive lymphomas.

USE OF A COMBINATION COMPRISING A BTK INHIBITOR FOR TREATING CANCERS

A method for the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject in need thereof a Btk inhibitor, particularly, (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor or a targeted therapy agent. A pharmaceutical combination comprising a Btk inhibitor, particularly, (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor or a targeted therapy agent.

CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE, PREPARATION, AND USES THEREOF

The present invention relates to a crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline form above in the treatment of a disease, or in the manufacturing of a medicament for the treatment of a disease.

CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION, AND USES THEREOF

The present invention relates to a crystalline form of (S) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahydropyrazolo [1, 5-a] pyri midine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline form above in the treatment of a disease, or in the manufacturing of a medicament for the treatment of a disease.

HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

The invention relates to a novel heterocyclic compound inhibiting a cyclin-dependent kinase (CDK) and a pharmaceutical composition comprising the same as an effective ingredient. The heterocyclic compound according to the present invention or pharmaceutically acceptable salt thereof can be effectively used in treating or preventing cancers, degenerative brain diseases, etc.

Copper(I)-Catalyzed Enantioselective Nucleophilic Borylation of Aliphatic Ketones: Synthesis of Enantioenriched Chiral Tertiary α-Hydroxyboronates

A new method was developed for the first catalytic enantioselective borylation of aliphatic ketones. A variety of substrates reacted efficiently with bis(pinacolato)diboron in the presence of a copper(I)/chiral N-heterocyclic carbene complex catalyst to furnish optically active tertiary α-hydroxyboronates with moderate to high enantioselectivities (up to 94 % ee). Notably, the product could be converted into the chiral tertiary alcohol derivative using a stereospecific boron functionalization process. The theoretical study of the mechanism for the enantioselectivity is also described.